anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This disclosure relates to an isolated and cloned DNA from a granulovirus virus which comprises an amino acid sequence of the viral gene encoding a polypeptide isolated from occlusion bodies of certain baculoviruses and which polypeptide possesses the biological activity of enhancing baculovirus infectivity. Such proteins termed herein as "enhancins" are found within the viral occlusion body, have a disruptive effect on the insect peritrophic membrane (PM) proteins, and/or interact with the midgut epithelium in such a manner as to permit the increased adsorption, penetration and uptake of virus particles by midgut cells with a concomitant increase in host mortality.  Disclosed herein is a recombinant DNA sequence which codes for the enhancin protein of the Helicoverpa armigera granulovirus virus. The DNA sequence is shown in SEQ. ID. NO. :1 and the open reading frame is shown in SEQ. ID. NO.:  1: base pairs 271-2976. The amino acid sequence of the enhancin protein is shown in SEQ. ID. NO.: 2.
The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy.
Participants will undergo simulation including Gd-EOB-DTPAenhanced MR and planning using minimal margins. Ten days later (+/- 3 days) participants will receive 40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance and on-line adaptive replanning.
An accurate estimation of COVID-19 contagion risk is important in terms of understanding the dynamic of disease transmission and health behavior. Previous research has documented that many health-related variables influence the risk estimation of communicable diseases. We expanded the current understanding by investigating whether health-irrelevant factors-such as one's sense of power-can have a systematic and consequential impact on perceived risks of catching the coronavirus. Based on the social distance theory of power, we propose that people in a higher power position develop a greater sense of social distance than those in a lower power position, which may in turn predispose the former to think that they are less likely to catch contagious diseases from other people. In Study 1, we provided correlational evidence that the personal sense of power was associated with the underestimation of contagion probability in Chinese university students. In Study 2, we established the causal relationship between power and concerns for contagious diseases in nonstudent adults and revealed the mediating role of social distance in the observed effect. Overall, these results, for the first time, indicate that power can elevate perceived social distance, exerting downstreaming effects on health cognition during the COVID-19 pandemic.
An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.
CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
BACKGROUND: The persistent left superior vena cava (PLSVC) is an infrequent vascular variant. PLSVC with absent right superior vena cava, also known as isolated PLSVC, is an exceptionally rare entity. In this case we present a patient with isolated PLSVC draining to coronary sinus, diagnosed incidentally during echocardiography.
CASE PRESENTATION: A 35-year-old man underwent a transthoracic echocardiography which showed an enormously dilated coronary sinus. Hand-agitated saline was injected via peripheral intravenous cannulas. The contrast appeared firstly in the coronary sinus before it opacified the right atrium. Since this was also visible by the right antecubital saline injection, it indicated an extremely rare case of PLSVC with the absence of right superior vena cava which was confirmed by cardiac magnetic resonance.
CONCLUSIONS: The finding of a distinctively dilated coronary sinus in echocardiography led us to further investigation using agitated saline that revealed an infrequent anomaly termed isolated PLSVC. The in-depth diagnosis of this vascular variant is crucial considering that it may lead to important clinical implications, such as difficulties with central venous access, especially in the current era of a rapid development of cardiac device therapies.
Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles. The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Cycles 1-3 will be administered without scheduled interruption every 28 days for a total of 12 weeks of therapy. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis. Blood glucose levels will be monitored immediately after HDMP infusion by finger stick glucometry. Two months following completion of treatment a response assessment will occur per iwCLL guidelines. The treatment will be administered as outpatient, and each cycle will be four weeks in duration.
BACKGROUND: Acute mastoiditis (AM) is a potentially life-threatening condition primarily affecting children. To date, there are no consistent criteria or valid guidelines for the diagnosis and treatment of pediatric AM. Therefore, this study evaluates the clinical course of AM in terms of clinical signs and treatment. In addition, a novel classification scheme for the disease and a treatment algorithm is being proposed.
METHODS: Patient records over a 12-year period from a single center were reviewed to identify confirmed cases of AM in children. Data collected included clinical signs, body temperature, and infection parameters during the disease, as well as radiological imaging, antibiotics, and surgical as well as conservative treatment. In addition, a classification of the AM stages was established in accordance with the findings described and practical experience, consisting of four stages (1, mastoidal irritation; 2, mild AM; 3, advanced AM; 4, advanced AM and additional complications) with corresponding treatment recommendations. In the retrospective cohort, those AM cases that were treated alongside the classification were compared with the rest concerning clinical course and outcome.
RESULTS: A total of 109 patients (mean age, 3.8 ± 3.8 years) were included. The main symptoms at hospital admission were auricular protrusion (n = 73; 67.0%), fever (n = 56; 51.4%) with a mean temperature of 38.3 ± 1.1°C, and otalgia (n = 28; 25.7%). The mean laboratory-tested levels of leukocytes and C-reactive protein at the time of hospital admission were 15.96 ± 8.7/nl and 59.6 ± 54.0 mg/L, respectively. During winter, there was a higher prevalence of AM, with peak hospital admissions in April (n = 22). The most common pathogen was Streptococcus pyogenes (32 cases). Treatment was purely conservative in four cases, whereas the remaining cases underwent surgery (41× grommet insertion, 64× plus mastoidectomy). The outcome was generally good, but in eight patients a second surgical procedure had to be performed as they showed signs of clinical deterioration. A total of 101 patients were treated according to the proposed algorithm, and all of which had a good outcome without the need for further interventions.
CONCLUSION: Based on clinical experience in a large cohort of pediatric AM patients, a novel diagnostic and treatment algorithm has been developed and successfully tested in a retrospective cohort for AM in children to prevent further complications and to ease its management by pediatricians and otorhinolaryngologists in the emergency setting.
The present invention describes a process for the production of a solid or semi-solid composition, in particular a solid oral composition for pharmaceutical use, which process comprises treating an enzyme or enzyme mixture having lipase activity and a surfactant component under defined process parameters. The method is suitable for reducing undesirable biological contamination, such as viral contamination, of the enzyme or enzyme mixture while maintaining a desired biological activity, such as an enzymatic activity. The process is suitable for industrial use. Also described are solid or semi-solid compositions comprising an enzyme or enzyme mixture having lipase activity, a surfactant component and a polymeric additive, optionally comprising other adjuvants. The composition may preferably be obtained by a process as described herein. The present invention also describes pharmaceutical compositions comprising a solid or semi-solid composition as described herein.
Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
To provide a biocompatible membrane composite including a cell impermeable layer and a mitigation layer.SOLUTION: A cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, the mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.SELECTED DRAWING: Figure 7A
A transmission device can be carried by the subject. A biological signal recording device can perform wireless communication with the transmission device. A transmitter transmits biological signal data corresponding to a biological signal of a subject. A storage stores the biological signal data. A receiver receives the biological signal data. A recorder records the biological signal data received by the receiver. A detector detects a missing portion in the biological signal data recorded by the recorder or a receipt of the biological signal data by the receiver. A notifier notifies the missing portion or transmits an acknowledgment of the receipt to the transmission device. A complementary transmitter retrieves biological signal data corresponding to the notified missing portion from the storage or identifies unreceived biological signal data and retrieves the identified biological signal data, and transmits the retrieved biological signal data. A complementary recorder records the biological signal data transmitted by the complementary transmitter.
In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
A pharmacokinetic-pharmacodynamic (efficacy) analysis was performed based on the pooled data from the 3 efficacy trials for partial-onset seizures. Lacosamide exposure is correlated with the reduction in seizure frequency. However, doses above 400 mg/day do not appear to confer additional benefit in group analyses.  
Cardiac Electrophysiology   
Electrocardiographic effects of lacosamide were determined in a double-blind, randomized clinical pharmacology trial of 247 healthy subjects. Chronic oral doses of 400 and 800 mg/day (equal to and two times the maximum daily recommended dose, respectively) were compared with placebo and a positive control (400 mg moxifloxacin). Lacosamide did not prolong QTc interval and did not have a dose-related or clinically important effect on QRS duration. Lacosamide produced a small, dose-related increase in mean PR interval. At steady-state, the time of the maximum observed mean PR interval corresponded with tmax. The placebo-subtracted maximum increase in PR interval (at tmax) was 7.3 ms for the 400 mg/day group and 11.9 ms for the 800 mg/day group. For patients who participated in the controlled trials, the placebo-subtracted mean maximum increase in PR interval for a 400 mg/day lacosamide dose was 3.1 ms in patients with partial-onset seizures and 9.4 ms for patients with diabetic neuropathy.
The maintenance of effect of SUNOSI in improving wakefulness and reducing excessive daytime sleepiness in patients with narcolepsy and OSA was assessed in two randomized-withdrawal, placebo-controlled studies, Study 3 (NCT02348619) and Study 4 (NCT02348632).) and Study 4 (NCT02348632).

Study 3 was a 6-week, multi-center, double-blind, placebo-controlled, randomized-withdrawal study in 174 adult patients with a diagnosis of OSA. The co-primary efficacy endpoints were change from the beginning to the end of the randomized withdrawal period in MWT and ESS. During a 2-week, open-label titration phase, patients were started on SUNOSI 75 mg once daily, and were titrated to the maximum tolerable dose between 75 mg and 300 mg per day (two times the maximum recommended daily dose). Patients were continued on this dose for a 2-week stable-dose phase. At the end of the stable-dose phase, 124 patients who reported “much” or “very much” improvement on the PGIc and who showed improvements on the MWT and ESS entered a double-blind withdrawal phase and were randomized 1:1 to either continue SUNOSI at the dose received in the stable-dose phase or switch to placebo. Compared to patients who remained on SUNOSI, patients randomized to placebo experienced statistically significant worsening of sleepiness as measured by the MWT and ESS (Table 8).

Study 4 was a 52-week, open-label study in 638 patients with either narcolepsy or OSA who had completed a prior trial. During a 2-week, open-label titration phase, patients were started on SUNOSI 75 mg once daily, and were titrated to the maximum tolerable dose between 75 mg and 300 mg per day (two times the maximum recommended daily dose). Patients remained on this dose during a subsequent open-label treatment period of either 38 (for patients previously enrolled in Study 1 or Study 2) or 50 (all others) weeks. A 2-week randomized-withdrawal period was incorporated into the study. After 6 months of stable-dose treatment, 282 patients (79 with narcolepsy; 203 with OSA) entered the randomized-withdrawal period. Patients were randomized 1:1 to either continue to receive SUNOSI at the dose received in the maintenance phase or to switch to placebo. The primary efficacy endpoint was change from the beginning to the end of the randomized-withdrawal period in ESS. Compared to patients who remained on SUNOSI, patients randomized to placebo experienced statistically significant worsening of sleepiness as measured by the ESS (Table 8).
PURPOSE: To provide an agent for preventing or inhibiting the progress of dental caries and containing the extract of KOBOKU (bark of Magnolia officinalis REHD. et WILS.), OREN (rhizome of Coptis chinensis FRANCH.) etc. or magnolol and honokiol which are the active components of the above extract.  
     CONSTITUTION: The objective agent contains the extract of KOBOKU, OREN, GOBAISHI (gall of Rhus chinensis MILL), GENNOSHOKO (whole grass of Geranium thunbergii SIEB. et ZUCC.), OBAKU (bark of Phellodendron amurense RUPR.), etc. and/or their active components (e.g. magnolol or formula I,  honokiol of formula II, berberine, etc.). The agent inhibits remarkably the  growth of Streptomyces mutans which is a cariogenic bacterium having the  strongest cariogenicity. The agent has somewhat milder activity than erythromycin, and lower side effects than antibiotic substances, and is suitable for administration for a long period. It also exhibits remarkable effect at a low concentration in a short time. Administered directly in the oral cavity, or by mixing with  tooth paste, or in the form of troche or sublingual tablet. 
     COPYRIGHT: (C)1982,JPO&Japio
Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity. As GLP-1 receptor agonists delay gastric emptying, perioperative healthcare practitioners could be concerned about an increased risk for pulmonary aspiration during general anaesthesia. We summarise relevant medical literature and provide evidence-based recommendations for perioperative care for people taking GLP-1 receptor agonists. GLP-1 receptor agonists delay gastric emptying; however, ongoing treatment attenuates this effect. The risk of aspiration during general anaesthesia is unknown. However, we advise caution in patients who recently commenced on GLP-1 receptor agonists. After over 12 weeks of treatment, standard fasting times likely suffice to manage the risk of pulmonary aspiration for most otherwise low-risk patients.
PURPOSE:To obtain a cosmetic, rich in ultraviolet ray protecting ability and having high transparency with hardly any paleness. CONSTITUTION:This cosmetic is obtained by blending amorphous type ultrafine particulate titanium oxide, subjected to the compounding treatment, obtained by a simultaneous vapor hydrolytic method of titanium tetraisopropoxide and an alkylalkoxysilane and having 7-40nm average particle diameter in an amount of 0.1-12 pts.wt. based on 100 pts.wt. product with a polyether-modified silicone in an amount of 0.1-12 pts.wt. based on 100 pts.wt. product.
Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain. A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. There are multiple binding sites available on beta-amyloid plaques. Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as \[11C\]PIB and \[11C\]SB-13. Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities. Therefore, we have recently developed \[11C\]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to evaluate \[11C\]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.
Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
Workaholism literature has been so far focused on individual differences in workaholic tendencies, considering the construct as a stable individual trait and highlighting its health and well-being consequences. Only recently, research has started inspecting the daily dynamics and potential consequences of state workaholism. In this preregistered study, we aimed at systematically investigating the within-individual fluctuations in workaholism levels and their potential short-term and delayed psychophysiological responses as captured by ambulatory assessment integrating subjective and objective data. Using an intensive longitudinal design over 10 workdays with 114 workers from various occupations (2,534 measurement occasions), we found higher systolic and diastolic blood pressure, emotional exhaustion, and sleep disturbances in workdays characterized by higher-than-usual workaholism symptoms. Moreover, the reactivity to state workaholism, as indexed by afternoon blood pressure, was found as a mediator of the subsequent prolonged activation indexed by bedtime blood pressure. Finally, we found evidence of a buffering effect of evening psychological detachment on the relationship between state workaholism and sleep disturbances. Overall, our results support the conceptualization of workaholism as a multilevel phenomenon that acts as an internal job-related demand by showing the typical strain reactions triggered by well-characterized external demands. This study contributes to the literature by highlighting that transient workaholism symptoms can result in significant short-term stress responses at different levels, providing new, robust, and multisource evidence that underlies the importance of effectively preventing and managing dysfunctional work investment since its early manifestation. (PsycInfo Database Record (c) 2024 APA, all rights reserved).